vTv Therapeutics Statistics
Want to see VTVT full AI Analyst Report?
vTv Therapeutics (VTVT) Stock Statistics & Valuation Metrics
Total Valuation
vTv Therapeutics has a market cap or net worth of $83.03M. The enterprise value is $305.99M.
- Market Cap
- $83.03M
- Enterprise Value
- $305.99M
Share Statistics
vTv Therapeutics has 3,953,928 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 3,953,928
- Owned by Insiders
- 11.48%
- Owned by Institutions
- 12.02%
Financial Efficiency
vTv Therapeutics’s return on equity (ROE) is -0.42 and return on invested capital (ROIC) is -39.41%.
- Return on Equity (ROE)
- -0.42
- Return on Assets (ROA)
- -0.30
- Return on Invested Capital (ROIC)
- -39.41%
- Return on Capital Employed (ROCE)
- -0.39
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.04M
- Employee Count
- 26
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of vTv Therapeutics is 715.67. vTv Therapeutics’s PEG ratio is -0.29.
- PE Ratio
- 715.67
- PS Ratio
- 2.30
- PB Ratio
- 3.83
- Price to FCF
- -3.91
- Price to Operating Cash Flow
- -12.28
- PEG Ratio
- -0.29
Income Statement
In the last 12 months, vTv Therapeutics had revenue of 0 and earned -26.97M in profits. Earnings per share was -3.20.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -32.81M
- Pretax Income
- -31.08M
- Net Income
- -26.97M
- EBITDA
- -31.06M
- Earnings Per Share (EPS)
- -3.20
Cash Flow
In the last 12 months, operating cash flow was -21.73M and capital expenditures 0, giving a free cash flow of -21.73M billion.
- Operating Cash Flow
- -21.73M
- Free Cash Flow
- -21.73M
- Free Cash Flow per Share
- -1.75
Dividends & Yields
vTv Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -25.60%
- Earnings Yield
- -2.88%
Stock Price Statistics
- Beta
- 0.66
- 52-Week Price Change
- -26.22%
- 50-Day Moving Average
- 29.24
- 200-Day Moving Average
- 33.26
- Relative Strength Index (RSI)
- 23.79
- Average Volume (3m)
- 35.35K
Important Dates
vTv Therapeutics upcoming earnings date is Mar 17, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 17, 2027
- Ex-Dividend Date
- ―
Financial Position
vTv Therapeutics as a current ratio of 13.54, with Debt / Equity ratio of 0.00%
- Current Ratio
- 13.54
- Quick Ratio
- 13.54
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 2.86
- Interest Coverage Ratio
- -5468.00
Taxes
In the past 12 months, vTv Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
vTv Therapeutics EV to EBITDA ratio is -0.91, with an EV/FCF ratio of -0.36.
- EV to Sales
- 0.21
- EV to EBITDA
- -0.91
- EV to Free Cash Flow
- -0.36
- EV to Operating Cash Flow
- -0.36
Balance Sheet
vTv Therapeutics has $77.16M in cash and marketable securities with $0.00 in debt, giving a net cash position of $77.16M billion.
- Cash & Marketable Securities
- $77.16M
- Total Debt
- $0.00
- Net Cash
- $77.16M
- Net Cash Per Share
- $19.52
- Tangible Book Value Per Share
- $5.61
Margins
Gross margin is 100.00%, with operating margin of -29.80%, and net profit margin of -20.84%.
- Gross Margin
- 100.00%
- Operating Margin
- -29.80%
- Pretax Margin
- -20.84%
- Net Profit Margin
- -20.84%
- EBITDA Margin
- -23.01%
- EBIT Margin
- -23.03%
Analyst Forecast
The average price target for vTv Therapeutics is $54.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $54.25
- Price Target Upside
- 152.68% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- 216600.00%
- EPS Growth Forecast
- 81.41%
Scores
- Smart Score
- 5
- AI Score
- 40
